Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis

[1]  B. Hutton,et al.  Treatment sequence network meta-analysis in Crohn’s disease: a methodological case study , 2019, Current medical research and opinion.

[2]  B. Feagan,et al.  Rapid Response to Vedolizumab Therapy in Biologic‐Naive Patients With Inflammatory Bowel Diseases , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  D. Rubin,et al.  Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials , 2018, Journal of Crohn's & colitis.

[4]  M. Dubinsky,et al.  Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease. , 2018, Inflammatory bowel diseases.

[5]  G. Kaplan,et al.  Real‐world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease , 2018, Alimentary pharmacology & therapeutics.

[6]  Siddharth Singh,et al.  Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium , 2018, The American Journal of Gastroenterology.

[7]  G. Kaplan,et al.  Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis , 2018, Therapeutic advances in gastroenterology.

[8]  G. Hather,et al.  Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease , 2018, Journal of Gastroenterology.

[9]  J. Colombel,et al.  Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease , 2018, Journal of Crohn's & colitis.

[10]  J. Colombel,et al.  Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease , 2018, Alimentary pharmacology & therapeutics.

[11]  F. Remzi,et al.  Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study. , 2018, Inflammatory bowel diseases.

[12]  B. Hutton,et al.  A152 TREATMENT SEQUENCE NETWORK-META ANALYSIS IN CROHN’S DISEASE , 2018 .

[13]  E. Loftus,et al.  Postoperative outcomes in vedolizumab‐treated Crohn's disease patients undergoing major abdominal operations , 2018, Alimentary pharmacology & therapeutics.

[14]  B. Feagan,et al.  Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease , 2018, Digestive Diseases and Sciences.

[15]  J. Xu,et al.  Efficacy of Vedolizumab in Fistulising Crohn’s Disease: Exploratory Analyses of Data from GEMINI 2 , 2018, Journal of Crohn's & colitis.

[16]  U. Kopylov,et al.  Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis , 2018, Journal of Crohn's & colitis.

[17]  B. Sands,et al.  OP025 Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis , 2018 .

[18]  Christopher Ma,et al.  P367 Vedolizumab and early postoperative complications in non-intestinal surgery: A case-matched analysis , 2018 .

[19]  C. Siegel,et al.  DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis , 2018 .

[20]  B. Sands,et al.  OP026 Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis , 2018 .

[21]  M. Murad,et al.  Systematic review with network meta‐analysis: first‐ and second‐line pharmacotherapy for moderate‐severe ulcerative colitis , 2018, Alimentary pharmacology & therapeutics.

[22]  Nima Hamidi,et al.  Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies , 2017, The Lancet.

[23]  A. Lightner,et al.  Surgical Outcomes in Vedolizumab-Treated Patients with Ulcerative Colitis , 2017, Inflammatory bowel diseases.

[24]  M. Neurath,et al.  Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles , 2017, Front. Immunol..

[25]  R. Fontana,et al.  Vedolizumab is safe and effective in moderate‐to‐severe inflammatory bowel disease following liver transplantation , 2017, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[26]  S. Travis,et al.  Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease , 2017, Alimentary pharmacology & therapeutics.

[27]  Siddharth Singh,et al.  Predictors of Clinical and Endoscopic Response with Vedolizumab for the Treatment of Moderately-Severely Active Ulcerative Colitis: Results from the us Victory Consortium , 2017 .

[28]  A. Amiot,et al.  Efficacy of Vedolizumab on Extraintestinal Manifestation in Patients with Inflammatory Bowel Diseases: A Post-Hoc Analysis of the Observ-IBD Cohort of the Getaid , 2017 .

[29]  M. Silverberg,et al.  Ulcerative Colitis Patients on Vedolizumab Lacking Response at Induction Phase Continue to Improve Over the First 6 Months of Treatment , 2017 .

[30]  C. J. Woude,et al.  Vedolizumab Induces Significantly Higher Endoscopic Remission Rates at Week 16 in Ulcerative Colitis as Compared to Crohn's Disease , 2017 .

[31]  R. Shivashankar,et al.  Effect of Vedolizumab Dose Escalation on Recapturing Response in Patients with Inflammatory Bowel Disease , 2017 .

[32]  A. Kaser,et al.  Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study , 2017 .

[33]  J. Ludvigsson,et al.  Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG) , 2017, Scandinavian journal of gastroenterology.

[34]  A. Ananthakrishnan,et al.  Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab , 2017, Digestive Diseases and Sciences.

[35]  R. Eliakim,et al.  Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—the Israeli Real-World Experience , 2017, Inflammatory bowel diseases.

[36]  A. Kaser,et al.  DOP021 Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study. , 2017, Journal of Crohn's & colitis.

[37]  C. Stansfield,et al.  P525 Effectiveness and safety of vedolizumab in IBD patients: a multicentre experience of "real world data" from the UK. , 2017, Journal of Crohn's & colitis.

[38]  S. Vermeire,et al.  Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[39]  B. Shen,et al.  P-134 Vedolizumab Use in Patients with IBD Undergoing Surgery: A Summary from Clinical Trials and Post-marketing Experience , 2017 .

[40]  G. Hather,et al.  P305 Indirect comparison of two novel biologics for the treatment of Crohn's disease : network-meta analysis of ustekinumab vs vedolizumab. , 2017, Journal of Crohn's & colitis.

[41]  M. Silverberg,et al.  P502 Ulcerative colitis patients on vedolizumab lacking response at induction phase continue to improve over the first 6 months of treatment. , 2017, Journal of Crohn's & colitis.

[42]  C. J. van der Woude,et al.  P447 Vedolizumab induces significantly higher endoscopic remission rates at week 16 in ulcerative colitis as compared to Crohn's disease. , 2017, Journal of Crohn's & colitis.

[43]  J. Colombel,et al.  P-135 A Description of Joint-Related Events in Patients Receiving Vedolizumab from Clinical and Post-marketing Safety Experience , 2017 .

[44]  B. Sands,et al.  DOP023 Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium. , 2017, Journal of Crohn's & colitis.

[45]  J. Hampe,et al.  Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study , 2016, Alimentary pharmacology & therapeutics.

[46]  A. Amiot,et al.  Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[47]  S. Cohen-Mekelburg,et al.  The Cost-Effectiveness of Vedolizumab for Inflammatory Bowel Disease: A Review of the Current Literature. , 2016, Gastroenterology & hepatology.

[48]  M. Dave,et al.  Vedolizumab for the Treatment of Crohnʼs Disease: Experience in an Inflammatory Bowel Disease Clinical Practice: 600 , 2016 .

[49]  J. Sanderson,et al.  Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres , 2016, Frontline Gastroenterology.

[50]  John T. Chang,et al.  The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium , 2016, American Journal of Gastroenterology.

[51]  S. Schreiber,et al.  Vedolizumab induction therapy for inflammatory bowel disease in clinical practice – a nationwide consecutive German cohort study , 2016, Alimentary pharmacology & therapeutics.

[52]  G. Lichtenstein,et al.  Tu1918 Safety of Vedolizumab in Inflammatory Bowel Disease Patients: Real World Experience From a Large University Practice , 2016 .

[53]  Siddharth Singh,et al.  Tu1908 Safety of Vedolizumab in Inflammatory Bowel Disease in a Multi-Center Real World Consortium , 2016 .

[54]  A. Charabaty,et al.  P-073 YI Single-Center Experience: Vedolizumab in Patients with Crohn's Disease and Ulcerative Colitis at Georgetown University Hospital , 2016 .

[55]  R. Longman,et al.  P-057 Harvey-Bradshaw Index Captures Clinical Efficacy of Vedolizumab Induction Therapy for Active Crohn's Disease , 2016 .

[56]  P. Rutgeerts,et al.  The safety of vedolizumab for ulcerative colitis and Crohn's disease , 2016, Gut.

[57]  Chien-Huan Chen,et al.  Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice. , 2016, Journal of Crohn's & colitis.

[58]  A. Ananthakrishnan,et al.  Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort , 2015, Inflammatory bowel diseases.

[59]  L. Stitt,et al.  Development of interim patient‐reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials , 2015, Alimentary pharmacology & therapeutics.

[60]  S. Glover,et al.  Efficacy of Vedolizumab in Crohnʼs Disease After at Least 14 Weeks of Therapy as Measured by HBI Scores: 1949 , 2015 .

[61]  M. Regueiro,et al.  Ulcerative Colitis Care Pathway. , 2015, Gastroenterology.

[62]  S. Bickston,et al.  Vedolizumab for Induction and Maintenance of Remission in Ulcerative Colitis: A Cochrane Systematic Review and Meta-analysis , 2015, Inflammatory bowel diseases.

[63]  A. Bitton,et al.  Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. , 2015, Gastroenterology.

[64]  Ashwin N. Ananthakrishnan,et al.  Epidemiology and risk factors for IBD , 2015, Nature Reviews Gastroenterology &Hepatology.

[65]  G. Kaplan,et al.  Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. , 2015, Gastroenterology.

[66]  M. Vandervoort,et al.  A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity , 2015, Alimentary pharmacology & therapeutics.

[67]  J. Xu,et al.  Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. , 2014, Gastroenterology.

[68]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[69]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[70]  J. Xu,et al.  Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease , 2013, Inflammatory bowel diseases.

[71]  M. V. van Oijen,et al.  Declining Risk of Colorectal Cancer in Inflammatory Bowel Disease: An Updated Meta-analysis of Population-based Cohort Studies , 2013, Inflammatory bowel diseases.

[72]  B. '. ’t Hart,et al.  Antagonizing the α4β1 Integrin, but Not α4β7, Inhibits Leukocytic Infiltration of the Central Nervous System in Rhesus Monkey Experimental Autoimmune Encephalomyelitis , 2013, The Journal of Immunology.

[73]  W. Sandborn,et al.  Crohn's disease , 2012, The Lancet.

[74]  K. Burke,et al.  Exclusive antagonism of the &agr;4&bgr;7 integrin by vedolizumab confirms the gut‐selectivity of this pathway in primates , 2012, Inflammatory bowel diseases.

[75]  D. Mould,et al.  Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose‐ranging Study , 2012, Inflammatory bowel diseases.

[76]  Meena Subramanyam,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.

[77]  A. Griffiths,et al.  Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements , 2012, The American Journal of Gastroenterology.

[78]  David Hunt,et al.  Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring , 2012, Practical Neurology.

[79]  J. Berger,et al.  Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteers: P-136. , 2011 .

[80]  L. Ngo,et al.  Asymptomatic reactivation of JC virus in patients treated with natalizumab. , 2009, The New England journal of medicine.

[81]  R. Egan,et al.  The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases , 2009, Journal of Pharmacology and Experimental Therapeutics.

[82]  B. Kuehn.  Rare neurological condition linked to newer monoclonal antibody biologics. , 2009, JAMA.

[83]  A. Cohen,et al.  Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[84]  S. Targan,et al.  Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. , 2007, Gastroenterology.

[85]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[86]  P. Rutgeerts,et al.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. , 2005, The New England journal of medicine.

[87]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[88]  F. Carbonnel,et al.  Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.

[89]  G. Greenberg,et al.  An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC) , 2000 .

[90]  C. FordAlexander,et al.  ULCERATIVE colitis. , 1997, Journal of the American Medical Association.

[91]  P. Munkholm,et al.  Disease activity courses in a regional cohort of Crohn's disease patients. , 1995, Scandinavian journal of gastroenterology.

[92]  E. Butcher,et al.  Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. , 1994, Journal of immunology.

[93]  B. Sands,et al.  Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy , 2017, Inflammatory bowel diseases.

[94]  Bin Zhou,et al.  Inflammation and Apoptosis: Dual Mediator Role for Toll-like Receptor 4 in the Development of Necrotizing Enterocolitis , 2017, Inflammatory bowel diseases.

[95]  V. Rai.  Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist , 2015 .

[96]  U. Kopylov,et al.  Optimizing anti-TNF treatments in inflammatory bowel disease. , 2014, Autoimmunity reviews.

[97]  S. Danese,et al.  Ulcerative colitis. , 2011, The New England journal of medicine.

[98]  G PLACITELLI,et al.  [Ulcerative colitis]. , 1958, La Riforma medica.